Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6

Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6

Giant cell arteritis (GCA) and polymyalgia rheumatica (RPM) are immune-mediated rheumatic disease (IMRDs), which typically develop in people over 50 years of age. Currently, GCA and PMR are considered within a single complex autoimmune-autoinflammatory pathology, defined as “GCA-PMR spectrum disease...

Full description

Saved in:
Bibliographic Details
Main Authors: Evgeny L. Nasonov, Azamat M. Satybaldyev, Elvira N. Otteva, Tatiana V. Beketova, Andrey A. Baranov
Format: Article
Language:Russian
Published: IMA PRESS LLC 2024-09-01
Series:Научно-практическая ревматология
Subjects:
giant cell arteritis
polymyalgia rheumatica
interleukin 6
interleukin 6 inhibitors
tocilizumab
Online Access:https://rsp.mediar-press.net/rsp/article/view/3600
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items